Skip to main content
TipRanks
Go Ultimate75% OFF

Orient Europharma Co., Ltd. (4120) AI Stock Analysis

TW:4120

Orient Europharma Co., Ltd.

(TPEx:4120)

Select Model
Rating:40Underperform
Price Target:TWD 40.00â–¼(-6.10% Downside)
Action:initiatedcoverage
Date:11/10/26

The overall score of 40 reflects a financially distressed company with deeply bearish market momentum. The most significant factor is the company's inability to generate profits or cash from operations, despite stable revenue and decent gross margins, which raises concerns about its cost structure and long-term viability. This fundamental weakness is mirrored in the technicals, with the stock in a clear downtrend and showing no signs of reversal. The high dividend yield is a red flag rather than an attraction, as it is likely unsustainable given the ongoing cash burn. The improved balance sheet is the only relative bright spot but is insufficient to offset the severe operational and market challenges.

Positive Factors
Improved Balance SheetThe substantial reduction in debt-to-equity gives Orient Europharma a more stable capital structure and greater resilience than in prior years. Lower leverage can reduce financial pressure and preserve flexibility to support operations or invest in growth while profitability recovers.
Negative Factors
Persistent LossesThe move from profit to sizable losses materially weakens earnings quality and makes future results less predictable. A negative operating result and approximately -12% net margin also reduce internal funding capacity, leaving recovery dependent on reversing cost and profitability pressures.

Orient Europharma Co., Ltd. (4120) vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%TW:4120+3.39%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 3.67B
Dividend Yield
9.39%
Average Volume (3M)
21.60K
Price to Earnings (P/E)
-6.8
Beta (1Y)
0.15
Revenue Growth
4.35%
EPS Growth
-17.92%
Country
TW
Employees
339
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Orient Europharma Co., Ltd. Business Overview & Revenue Model

Company Description

Orient EuroPharma Co., Ltd. (OEP) operates as a global pharmaceutical enterprise, engaged in the development and production of various medications. Its portfolio of prescription pharmaceuticals encompasses treatments for a wide array of conditions, s...

Orient Europharma Co., Ltd. Financial Statement Overview

Summary

Financial performance is weak. While gross margins are healthy (43-47%) and the balance sheet has improved via deleveraging (debt-to-equity down to 0.52), the company is deeply unprofitable. The TTM net loss of NT$567 million, negative EBIT margins, and a return on equity of -9.0% indicate severe operational inefficiencies. Critically, operating and free cash flows are persistently negative, signaling a cash burn that threatens financial stability.

Income Statement

38Negative

Balance Sheet

55Neutral

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.65B4.60B4.39B4.59B4.73B4.77B
Gross Profit2.17B2.10B2.07B2.15B2.03B2.15B
EBITDA-145.21M-121.76M183.90M596.88M-34.15M133.32M
Net Income-538.56M-567.39M-283.93M143.94M-310.80M120.17M
Balance Sheet
Total Assets11.75B12.21B11.57B10.81B10.43B9.40B
Cash, Cash Equivalents and Short-Term Investments1.67B2.12B1.89B2.14B1.95B2.06B
Total Debt3.53B3.27B4.23B4.84B5.03B4.23B
Total Liabilities5.41B4.85B5.75B6.65B6.99B5.95B
Stockholders Equity5.23B6.29B5.16B3.51B2.93B2.94B
Cash Flow
Free Cash Flow-825.61M-472.30M-221.31M20.28M-859.84M-1.49B
Operating Cash Flow-598.50M-298.63M-121.11M120.98M-218.75M77.65M
Investing Cash Flow120.45M1.62B465.20M62.11M-611.56M-1.50B
Financing Cash Flow-105.50M-1.05B-760.92M-209.71M428.31M1.36B

Orient Europharma Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:4120 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:1777TW:177782OutperformTWD 3.33B9.02―5.36%1.01%41.25%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:1786TW:178650NeutralTWD 3.52B24.28―4.05%-2.25%-15.57%
TW:4120TW:412040UnderperformTWD 3.70B-6.76―9.39%4.35%-17.92%
TW:6875TW:687537UnderperformTWD 3.15B-8.94――-60.37%-77.11%

* General Sector Average

Performance Comparison

0%50%100%TW:4120TW:1777TW:1786TW:6634TW:6875TW:6885Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:4120 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:4120Orient Europharma Co., Ltd.42.601.403.39%
TW:1777SYN-TECH Chemical & Pharmaceutical Co. Ltd.74.602.072.85%
TW:1786SciVision Biotech Inc.47.10-26.70-36.18%
TW:6634Sinew Pharma, Inc.57.7018.7047.95%
TW:6875Pharmosa Biopharm Inc.24.40-22.15-47.58%
TW:6885BRIM Biotechnology, Inc.27.75-0.95-3.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026